The Limited Times

Now you can see non-English news...

Leukemia, new treatment works. Effectiveness also proven by AI

2022-12-14T08:29:50.684Z


Inst. Amadori, disease remission in 89% of cases with 'combo' therapy (ANSA) A new 'combo' therapy has proven effective against acute myeloid leukemia and the positive effects of the treatment have been highlighted by clinical trials but also by a virtual trial conducted through artificial intelligence, presented for the first time at the Congress of the American Society of hematology (Ash).     The two studies - presented with the 'Best of Ash' mention - were conceived by


A new 'combo' therapy has proven effective against acute myeloid leukemia and the positive effects of the treatment have been highlighted by clinical trials but also by a virtual trial conducted through artificial intelligence, presented for the first time at the Congress of the American Society of hematology (Ash).


    The two studies - presented with the 'Best of Ash' mention - were conceived by the Romagna Institute for the treatment of tumors Nino Amadori of Meldola, and carried out in 30 centers of the 'Fondazione Gimema' network for the promotion of research on haematological diseases'.


    "Our study - explains the scientific director of the Amadori Institute, Giovanni Martinelli to ANSA - demonstrated the effectiveness of the new Vflai program, which provides for chemotherapy associated with the new drug venetoclax, in young patients with newly diagnosed acute myeloid leukemia and at a higher risk of recurrence, with an unfavorable profile.


    In fact, Vflai led to a complete remission of the disease in 89% of cases, a complete remission figure never obtained in this type of population.

The study was conducted on 117 patients and at ASH we are presenting the results on the first 60 patients". The Institute also carried out a second analysis through a virtual trial called the Propensity score: "We considered a historical series of patients with acute leukemia compared to the treatment with Vflai and it has been seen that this approach is extremely more favorable than the conventional chemotherapy in use". The virtual trial approach, underlines Martinelli, "is very innovative because many patients are spared a clinical trial in which they could occur even in the least effective trial arm.

AND'

one of the first times that a virtual trial has been presented: the idea is to create an experiment with artificial intelligence that has the same characteristics and the same effectiveness as a real trial". In Italy there are around 6,000 cases of acute myeloid leukemia, of which half are subjects between 18 and 65 years of age. The majority of these patients then undergo a consolidation bone marrow transplant. "It is therefore important to arrive at the transplant without residual disease: our data indicate that this is an innovative therapy.

The patient is put in a healing condition which - concludes Martinelli - can then be consolidated by the transplant".

artificial intelligence an experiment that has the same characteristics and the same efficacy as a real trial". patients then undergo a consolidation marrow transplant." It is therefore important to arrive at the transplant without residual disease: our data indicate that this is an innovative therapy.

The patient is put in a healing condition which - concludes Martinelli - can then be consolidated by the transplant".

artificial intelligence an experiment that has the same characteristics and the same efficacy as a real trial". patients then undergo a consolidation marrow transplant." It is therefore important to arrive at the transplant without residual disease: our data indicate that this is an innovative therapy.

The patient is put in a healing condition which - concludes Martinelli - can then be consolidated by the transplant".

The majority of these patients then undergo a consolidation bone marrow transplant.

"It is therefore important to arrive at the transplant without residual disease: our data indicate that this is an innovative therapy. The patient is put in a state of recovery which - concludes Martinelli - can then be consolidated by the transplant".

The majority of these patients then undergo a consolidation bone marrow transplant.

"It is therefore important to arrive at the transplant without residual disease: our data indicate that this is an innovative therapy. The patient is put in a state of recovery which - concludes Martinelli - can then be consolidated by the transplant".


Source: ansa

All life articles on 2022-12-14

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.